Kornimate/medical-research-clean huggingface dataset:
umbilical cord(uc)-derived mesenchymal stem cells(mscs) treatment for the 2019-novel coronavirus(ncov) pneumonia

Conditions: Pneumonia, Viral; Pneumonia, Ventilator-Associated

Summary: serious pneumonia and critical pneumonia caused by the 2019-ncov infection greatly threats patients' life, uc-mscs treatment has been proved to play a role in curing multiple diseases. and this study is conducted to find out whether or not it will function in 2019-ncov infection pneumonia.

serious pneumonia and critical pneumonia caused by the 2019-ncov infection greatly threats patients' life, uc-mscs treatment has been proved to play a role in curing multiple diseases. and this study is conducted to find out whether or not it will function in 2019-ncov infection pneumonia. and we are going to get the permission of the enrolled patients. besides the present clinical treatment, uc-mscs treatment will be applied to those fulfilling the enrollment. after a period of uc-mscs treatment, the analysis of uc-mscs treatment will be completed from related aspects.

Eligibility criteria:
inclusion criteria: * 18-80 years old ,no gender restriction * according to diagnosis and clinical management of pneumonia caused by 2019-ncov infection(trial version 6), patients are diagnosed with severe or critical 2019-ncov pneumonia * women of childbearing age should have a negative blood pregnancy test before the start of dosing and agree to take effective contraceptive measures during the trial until the last follow-up (28 days) * previous detection of nucleotide or antibody of 2019-ncov pneumonia was positive * voluntarily participate in this clinical study and sign a written informed consent. if the patient cannot obtain informed consent, he can authorize his legal representative. exclusion criteria: * liver sofa score of more than 3 points; * hiv positive * highly allergic constitution or history of severe allergies; * pregnant and lactating women; * patients with malignant tumors; * patients with previous history of pulmonary embolism; * participating in clinical trials of other drugs within 3 months before enrollment. * be thought by researchers to be inappropriate to participate in this clinical study.

Keywords: 2019-ncov infection uc-mscs treatment
osteoporosis disease management demonstration project (0000-037)

Conditions: Osteoporosis

Summary: the purpose of this study is to assess the impact of disease management interventions on bone mineral density (bmd) screening rates and osteoporosis treatment rates in women age 65 years or older.


Eligibility criteria:
inclusion criteria: * members of the henry ford health system exclusion criteria: * individuals who are not members of the henry ford health system
enhancement of methylphenidate treatment by psychosocial intervention and support

Conditions: Attention Deficit-/Hyperactivity Disorder

Summary: the main purpose of this study is to evaluate the effectiveness of a parenting enhancement training (pet) for parents with children diagnosed with attention deficit-/hyperactivity disorder (adhd) who are already medicated with methylphenidate.

the main purpose of this study is to evaluate the effectiveness of a parenting enhancement training (pet) for parents with children diagnosed with attention deficit-/hyperactivity disorder (adhd) already medicated with methylphenidate (mph). this particular pet was developed at the department of child and adolescent psychiatry and psychotherapy at the university of cologne and has already been evaluated in several studies. mph treatment has been proven to be efficacious in the reduction of adhd symptoms. however, despite optimal titration a substantial percentage of children still suffer from residual symptoms and impairment in psychosocial functioning. therefore, there is still room for improvement in satisfaction with medication. moreover, a substantial rate of patients with good treatment effects fails to comply with medication during the course of treatment. this parenting enhancement training (pet) mainly conducted via written materials and telephone support will be introduced in patients already treated with mph. effects are expected on symptoms of adhd as well as on comorbid oppositional symptoms. further outcome parameters are satisfaction with medication and medication compliance of mph treatment, psychosocial functioning as well as parenting skills. parenting skills are a main focus of the pet and adhd symptoms shall be improved through improving parenting skills. besides focusing on symptoms, recent research often focuses on improvement of quality of life and impairment in psychosocial functioning (e. g. family, school, leisure time) as well. not only suffer patients from the main symptoms. many patients suffer as well from the symptoms' consequences, which is often an overall impairment. satisfaction with medication and medication compliance are fundamental conditions for the success of a long term medical therapy. however, many studies show a lack of compliance.

Eligibility criteria:
inclusion criteria: * the child attends school and is aged 6 to 12 * primary diagnosis of adhd * medication with methylphenidate in stable doses for at least two months * currently, no change of medication is planned * the parents are motivated to participate in the parenting enhancement training * the parents have a command of written and spoken german * psychosocial impairment measured with wfirs-p exclusion criteria: - the family takes presumably part in psychotherapy with an intensive parenting training component during the duration of the intervention

Keywords: attention deficit-/hyperactivity disorder parenting enhancement training guided self-help methylphenidate
use of different treatment care methods in patients with dementia associated with alzheimer's disease

Conditions: Dementia; Alzheimer's Disease

Summary: the purpose of this observational study is to examine patterns of treatment care for patients with alzheimer's disease (ad) in a real-world arena and to examine the association with different outcomes for patients and informal caregivers.

this is a 2-year, multicenter, prospective (look forward using periodic observations collected predominantly following patient enrollment), longitudinal (it is a co relational research study that involves repeated observations of the same variables over long periods of time), and observational study. the objective of this study is to examine the patients with mild and moderate ad who are currently being treated with different treatment care methods in real-world settings. doctors will not be provided medication or asked to treat their patients with any particular treatment. the effect of the different management strategies on cognition, activities of daily living, and behavior of the patients will be evaluated, and data on the informal caregiver burden will be assessed. data on the utilization of health and social care services by the patient and the primary informal caregiver, including admission of the patient to an assisted living facility or nursing home will be assessed. the doctor's assessment of clinical global impression and adverse events will also be documented. data will be collected from the doctors at baseline and at 6, 12, and 24 months, and from the caregivers at baseline and 6, 12, 18, and 24 months. the medication dosage and administration is based upon the doctors' prescription, individualized for the patient and not dictated by the protocol.

Eligibility criteria:
inclusion criteria: * have a physician-based diagnosis of mild to moderate alzheimer's disease (mini-mental state examination \[mmse\] score between 10-24) * must be living at home or in a facility for the elderly (eg, assisted living), who live with or have frequent visits from a friend or relative (caregiver) or with a behavioral symptom (eg, as agitation or wandering) * have no plan to change the current treatment plan for at least 90 days exclusion criteria: * have been using an acetylcholinesterase inhibitor or memantine currently but have used one in the past 30 days * must be residing in or planning to move to a nursing home within the next 90 days or patients participating in another clinical trial

Keywords: dementia alzheimer's disease acetylcholinesterase inhibitor galantamine nursing home admission
influence of beliefs on the development of musculoskeletal pain.

Conditions: Musculoskeletal Pain

Summary: musculoskeletal pain is highly prevalent, disabling, and with high socio-economic costs, with many negative effects on quality of life. it affects the ability to perform work, social, recreational and domestic tasks, changing the mood and concentration of this population. despite the worldwide prevalence and socioeconomic burden of this condition, a clear understanding of its etiology and pathogenesis remains elusive. aims: (i) to analyze the possible level of association between fear of pain, fear of movement, self-efficacy, and pain acceptance on pain-disability at the start of the study and prospectively evaluate its role as a risk factor; (ii) to evaluate the possible role as a prognostic factor of fear of pain, fear of movement, self-efficacy and pain acceptance in those who develop musculoskeletal pain at follow-up; (iii) explore the possible mediating power of fear of movement and self-efficacy in the relationship between pain-disability; (iv) investigate what percentage of the variance accounts for beliefs (fear of pain, fear of movement, self-efficacy, and acceptance of pain) in predicting the onset and / or maintenance of musculoskeletal pain.

the present study will be a prospective observational study of 4 years that will be carried out between september 2017 and september 2020 at the university of malaga. several questionnaires assessing different beliefs associated with pain will be administered to participants. the results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months. it will be implemented and reported in line with the spirit statement and the strobe guidance. participants a consecutive sample of healthy male and female students, students of the university of málaga, will be recruited. research assistants trained by the principal investigator will be in charge of carrying out the recruitment and evaluating the participants for their eligibility. participants who meet the inclusion criteria will be invited to participate in this study, and then evaluated at baseline and at 12, 24, 36 and 48 months of follow-up. the inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the university of málaga belonging to one of the disciplines previously mentioned. the exclusion criteria are as follows: (i) participants currently experiencing musculoskeletal pain; (ii) participants currently taking medication; (iii) previous histories of musculoskeletal surgery; (iv) inability to provide written informed consent and / or complete questionnaires.

Eligibility criteria:
inclusion criteria: * men / women over 18 years. * students of the university of málaga. exclusion criteria: * participants currently experiencing musculoskeletal pain. * participants currently taking medication. * previous histories of musculoskeletal surgery. * inability to provide written informed consent and / or complete questionnaires.

Keywords: chronic pain psychological factors musculoskeletal pain prognosis
study to evaluate the safety and efficacy of asc40 in subjects with moderate to severe acne vulgaris

Conditions: Acne Vulgaris

Summary: this is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. the subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.


Eligibility criteria:
key inclusion criteria: * 18-40 years old (including 18 and 40 years old); * investigator's global assessment of subject at baseline period was at 3-4. * facial skin lesions of subject need counting as follows: 30 \~ 75 inflammatory lesions (the total number of papules, pustules and nodules is 30 \~ 75, including no more than 2 nodules), 30 \~ 100 non-inflammatory lesions (the total number of open and closed comedones is 30 \~ 100); key exclusion criteria: * known to be allergic or hypersensitive to asc40 tablets; * facial nodules of subject is more than 2 facial nodules * the subject with cystic acne * subject with secondary acne such as occupational acne (e.g., chloroacne) and acne caused by corticosteroids (e.g., chloroacne or acne caused by drugs); * serum ast, alt≥3uln and cr exceeded the upper limit of normal range

Keywords: acne vulgaris asc40
study of dc-ctl combined with cik for advanced solid tumor

Conditions: Colorectal Cancer; Renal Cell Carcinoma; Nasopharyngeal Carcinoma; Lung Cancer

Summary: background: combinations of dendritic and cytokine-induced killer cells (dc-cik) and cytokine-induced killer cells (cik) treatment may enhance the immune response and stop cancer cells from growing. the investigators suppose that dc-cik combined with cik treatment will improve the prognosis of advanced solid tumors. objective: phase ii clinical trial to investigate the efficacy of concurrent chemotherapy with dc-cik and cik treatment in patients with treatment-refractory solid tumors. study treatment: patients in group a will receive 4 cycles of cik treatments and 4 cycles of dc-cik treatments within 8 months. patients in group b will have no immunotherapy . chemotherapy are available in both groups.


Eligibility criteria:
inclusion criteria: 1. patients with treatment-refractory advanced colorectal cancer can not accept operation . 2. age 18 to 75 years.eastern cooperative oncology group (ecog) score ≤ 2 points, estimate survival \> 3 months; 3. blood white blood cell(wbc)≥ 4×109/l, hb ≥ 100g/l, platelet count(plt)≥ 80×109/l; alanine aminotransferase(alt) and aspartate aminotransferase(ast)≤ 2 times of normal upper value; serum cr ≤ 2 normal upper value; 4. without any other malignant disease; 5. with more than one scalable lesions 6. patients voluntary attempt, and informed consent. 7. women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus. exclusion criteria: 1. patients who do not conform to the inclusion criteria;; 2. patients with uncontrolled infection; underlying disease that was severe or life-threatening(such as uncontrolled brain metastasis ); patients who were pregnant or lactating; 3. ecog perform status ≥ 2; 4. other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)..

Keywords: cytokine-induced killer cell dendritic and cytokine-induced killer cells
treatment of patients with relapsed or primary refractory aggressive b- cell nhl

Conditions: Lymphoma, High-Grade

Summary: phase ii study for treatment of patients with relapsed or primary refractory aggressive b- cell nhl and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

phase ii study for treatment of patients with relapsed or primary refractory aggressive b- cell nhl and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation. aim is to find response rates and duration of combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory cd 20 positive b cell nhl.

Eligibility criteria:
inclusion criteria: * histologically proven high grade b-nhl (cd 20 \>= 20 % positive) * age \>= 18 years * at least one pretreatment with anthracycline polychemotherapy +/- radiatio: * first relapse nad contraindication for aggressive salvage therapy e.g. high dose therapy with autologous stem cell transplantation * second relapse (after aggressive salvage therapy) * patient's refusal of aggressive salvage therapy in first relapse * informed consent exclusion criteria: * untreated patients * pretreatment with bendamustine * primary cns- lymphoma * karnofsky index \< 50 (except caused by lymphoma) * hiv positive, hepatitis b or c * serious concurrent disease * non-compensated heart failure (\>=nyha 3) * non-compensated hypertension * renal insufficiency (creatinine \> 2.0 mg/dl), not related to lymphoma * hepatic insufficiency with transaminase values greater than 3-fold of normal values and/or bilirubin levels \> 200 µmol/l, not related to lymphoma * missing compliance respective incapability to comply (e.g.cerebral dysfunction * pregnancy * hematopoetic insufficiency not lymphoma related (leucocyte count \<= 2500/µl, granulocyte count \<= 1000/µl, platelet count \<= 80000/µl)

Keywords: relapsed refractory cd 20 positive
maternal telemental health interventions in response to covid-19*

Conditions: Perinatal Depression; Specific Phobia; Perinatal Anxiety

Summary: the purpose of this study is to assess the effectiveness of a telemental health intervention on the mental health of pregnant women during the covid-19 crisis in qatar.

a list of potential participants, including contact information, will be extracted from women wellness and research center's registry. a probability sampling technique (simple random selection) will be employed to randomly select (automated random number generator) the potential participants. then, the potential participants will be contacted and informed about the study. after consenting to participate, they will be screened for eligibility. the pregnant women who met the inclusion criteria will be enrolled and followed up until nine months after delivery. the contact details of each participant will be written on a paper and sealed in an envelope marked with either letter a or b. upon enrolment, the participants will be randomized equally with a block size of two into two parallel arms. the pregnant women in the interventional arm will receive six sessions of a low-intensity psychosocial intervention through telemental health consultations with a trained psychologist. on the other hand, those in the control arm will not receive any intervention. the participants in both arms will be screened for psychological distress (six times) over the study period.

Eligibility criteria:
inclusion criteria: 1. all pregnant women of reproductive age (18- 49) years old in the second trimester that agree and consent to receive teleconsultation. 2. no specific nationality restriction. 3. language communicated english and arabic. 4. able to cooperate with data collection procedure. exclusion criteria: 1. pregnant women with psychiatric illness and following up at sidra or hmc mental services. 2. pregnant women receiving mental health medications (antidepressants.) 3. cannot communicate in english or arabic. 4. didn't consent.

Keywords: telepsychiatry maternal mental health low-intensity psychosocial interventions
metastatic colorectal cancer database

Conditions: Metastatic Colorectal Cancer

Summary: the metastatic colorectal cancer (mcrc) database base contains data collected during the regular clinical patient management in centre georges francois leclerc, dijon.

the metastatic colorectal cancer (mcrc) database base contains data collected during the regular clinical patient management (sociodemographic, clinical, pathological, radiological, biological, disease evolution, ...). this database allows easy access to information in a centralized and structured way. this cohort is used to gather insights for research purposes. all data collected come from medical files of patients managed at centre georges francois leclerc, dijon, france.

Eligibility criteria:
inclusion criteria: * metastatic colorectal cancer * age \>= 18 exclusion criteria: * non metastatic colorectal cancer * objection to the use of medical data records

Keywords: metastatic colorectal cancer
iron therapy in erythropoietic protoporphyria

Conditions: Erythropoietic Protoporphyria; Iron-deficiency

Summary: giving oral iron to patients with erythropoietic protoporphyria (epp) who is iron deficient is thought to be beneficial. this is, however, not well documented. the purpose of this study is to investigate the effect and safety of oral iron in patients with epp who is taking iron tablets due to iron deficiency.


Eligibility criteria:
inclusion criteria: * diagnosed with epp * taking standard dose of iron tablets due to iron deficiency exclusion criteria: * pregnant * lactating
a lifestyle intervention for type 2 diabetes patients in kuwait and its impact on glycaemic control

Conditions: Diabetes Mellitus, Noninsulin-Dependent; Diabetes, Type 2

Summary: this was an unblinded, randomised controlled study, the purpose of which was to investigate the impact of a structured health education intervention on the glycaemic control of type 2 diabetes patients within a kuwaiti cultural context.

the control group continued to receive routine clinical advice, in addition to the individual session. the intervention group was enrolled in a structured group-based educational program for the duration of the study (12 months). physical, physiological and biochemical outcome measures were assessed at baseline and then at a 12-month follow up. the total duration of the study, including the recruitment, the screening, the pilot study, the educational sessions and the follow-up, was 14 months altogether, from december 2014 to february 2016. the study consisted of the following three phases. * phase 1: included the initial recruiting of diabetes patients at an al-rehab polyclinic and the baseline assessment of their medical, dietary and physical activity history, in addition to the biochemical assessment. * phase 2 (pilot study): five patients were chosen from the recruited patients for a pilot study to be monitored for one whole month (30 days) in order to evaluate the lifestyle intervention's safety, its compliance to the educational sessions, and anticipated barriers and results. recruitment continued during the pilot study. * phase 3 (main study): this phase was based on recommending lifestyle intervention to the intervention group of diabetes patients. the educational sessions were scheduled every two weeks and a total of four sessions was provided. both intervention and control groups were received individual sessions at the beginning and at the end of the study. later, there was a follow up of the intervention and the control groups at the end of the study, to measure the intervention's effectiveness and evaluate the results.

Eligibility criteria:
inclusion criteria: * type 2 diabetes, treated with diabetes medications but not on insulin only, and who had other chronic diseases associated with diabetes, such as hypertension and hyperlipidaemia exclusion criteria: * history of major disabilities such as cardiovascular disease (cvd), an inability to walk, cancer, and chronic obstructive pulmonary diseases (copd).